Alnylam Pharmaceuticals has recently secured multiple victories in the market, having received FDA approval for
AMVUTTRA® (vutrisiran), the first RNAi Therapeutic aimed at reducing cardiovascular failure, hospitalizations and urgent heart failure visits in adults suffering from ATTR Amyloidosis with Cardiomyopathy (ATTR-CM). This announcement has led equity researcher Needham to raise the price target for Alnylam to a whopping $377. Additionally, Alnylam appointed a new Chief R&D Officer to foster growth. The company's forecast appears bright with robust revenue growth reported for Q1 2025. Furthermore, Alnylam's product,
vutrisiran, received positive CHMP opinion for the treatment of ATTR Amyloidosis with Cardiomyopathy and was met with acclaim in the market, with the company's stock hitting an all-time high of $311.24. Alnylam also faced healthy competition as their drug, developed to battle cardiomyopathy, posed a threat for Pfizer, BridgeBio Pharma. The company also raised the price target to $360 buoyed by strong
vutrisiran sales. The approval of Qfitlia™ (fitusiran), the first siRNA for the treatment of Haemophilia A or B further substantiates Alnylam's dominance in innovation.
Alnylam Pharmaceuticals News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Thu, 26 Jun 2025 13:44:48 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -2
